Moscow, 04th August 2021 – The Ministry of Health of the Russian Federation granted marketing authorization for a new tetravalent influenza vaccine manufactured by the Saint-Petersburg Scientific Research Institute of Vaccines and Serums of the FMBA of Russia. The Saint-Petersburg Scientific Research Institute of Vaccines and Serums has developed and manufactures the vaccine according to the full-cycle technology. The clinical trials of Flu-M Tetra engaged more than 500 volunteers aged from 18 to 60. The new vaccine forms the immunity against four existing influenza virus strains in accordance with the World Health Organization (WHO) recommendations. Flu-M vaccines are manufactured according to the original technology, which, ensures less content of chicken protein as compared to the foreign equivalents, which is particularly important for allergic people. The Institute’s manufacturing capacities in Krasnoe Selo are able to produce approximately 20 mn doses of tetravalent vaccine per year. The enterprise plans to enhance its capacities up to 40 mn doses by the next season. WHO emphasizes the importance of influenza prevention amidst the continuing outbreak of the new coronavirus infection.
More information available at https://spbniivs.ru/en/press-center/fmba-registers-new-influenza-vaccine/
